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Background/Aims: Noninvasive markers of liver fibrosis in 
alcoholic liver disease (ALD) are crucial to establish early in-
tervention. Previous studies have suggested that plasma lev-
els of cleaved keratin-18 (K18; M30) fragments can predict 
the severity of liver disease. The aim of this study was to cor-
relate plasma M30 levels with stages of liver fibrosis in ALD. 
Methods: Patients with ALD (n=139, 79.1% males) and liver 
histology were included, and plasma samples were collected 
to quantify plasma M30 levels. Patients were stratified into 
five groups by fibrosis stage (F0=14; F1=15; F2=35; F3=17; 
and F4=58) according to the Kleiner score. Differences be-
tween groups were evaluated using the chi-square test or 
analysis of variance. Trends by fibrosis stage were calculated 
by logistic regression analysis, and sensitivity, specificity and 
positive and negative predictive values were determined. 
Results: There were no significant differences in M30 levels 
among fibrosis stages. The correlation between plasma M30 
levels and fibrosis was poor (Pearson’s correlation coeffi-
cient=0.13, Spearman rho=0.20 [p=0.02]), and M30 levels 
did not correlate with alcohol-specific histological features. 
However, significant correlations of M30 levels with aspar-
tate aminotransferase (Spearman rho=0.653, p<0.001) and 
alanine aminotransferase (Spearman rho=0.432, p<0.001) 
were found. M30 levels of >200 U/L reveal a sensitivity 
for predicting cirrhosis of 84.5% with a negative predictive 
value of 73.5%. Conclusions: Plasma M30 levels are often 
elevated in ALD and correlate with serum transaminases 
but do not reflect fibrosis. The usefulness as a prognostic 
marker awaits evaluation in prospective studies. (Gut Liver 
2019;13:77-82 )
Key Words: Apoptosis; Caspases; Fibrosis progression; Non-
invasive diagnosis
INTRODUCTION
Alcoholic liver disease (ALD) due to excessive alcohol con-
sumption remains one of the major causes of chronic liver 
disease, ranging from simple steatosis to alcoholic hepatitis, fi-
brosis/cirrhosis, and hepatocellular carcinoma (HCC).1 However, 
the pathophysiological causes of disease progression still remain 
poorly understood. Approximately 20% of patients with alco-
holic steatosis progress to fibrosis and cirrhosis, particularly if 
they continue to drink.2-4 Timely diagnosis of the severity of liv-
er damage is crucial to allow for effective counselling and ther-
apeutic interventions. Liver biopsy with histologic evaluation of 
tissue damage is the gold standard in the differential diagnosis 
of liver diseases, but they cannot be performed as a follow-up 
test in short-term intervals, carry a relevant procedure-related 
risk, and can lead to misclassification due to sampling error.5,6 
Thus, noninvasive assessment of the severity of alcoholic fi-
brosis using surrogate markers that reliably reflect the extent 
of liver scarring, for example, fibrosis, and offer prognostic in-
formation is pivotal to allow for risk-guided intervention, easy 
follow-up during therapy, and risk reduction for patients.
To this end, several noninvasive methods including serum 
hyaluronic acid levels and several composite scores such as the 
Enhanced Liver Fibrosis (ELF) score, fibrosis-4 (FIB4) score and 
aspartate aminotransferase (AST) to platelet ratio index (APRI) 
were evaluated to assess fibrosis in alcoholic liver damage. 
However, the positive predictive values for mild and moderate 
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fibrosis remain suboptimal.7 More recently, transient elastogra-
phy (FibroScan) that measures liver stiffness has proven more 
useful and has become an integral part of the diagnostic armory 
in the assessment of the severity of fibrosis in ALD.8,9
Additionally, earlier studies in patients with nonalcoholic fat-
ty liver disease (NAFLD) indicate that plasma levels of cleaved 
keratin-18 (K18) fragments predict histological nonalcoholic 
steatohepatitis (NASH) and severity of disease including fibro-
sis.10,11 K18 is a cytoskeletal protein which represents one of 
the main intermediate filament peptides in hepatocytes. During 
hepatocellular cell death, K18 is released from decaying hepato-
cytes into the blood stream. During apoptotic cell death, K18 is 
cleaved by caspases and the resulting cleavage products can be 
captured using an enzyme-linked immunosorbent assay (ELISA). 
While levels of cleaved K18 fragments (referred to as M30 levels 
in this manuscript) are considered relatively specific for apop-
totic cell death, non-cleaved K18 levels (M65) reflect total cell 
death from both apoptosis and necrosis.12 Subsequent studies 
showed that although plasma M30 levels have a high specificity 
for NAFLD and associated fibrosis, its usefulness as a screening 
test for staging NASH was limited due to low sensitivity,13 and 
a later meta-analysis confirmed a sensitivity of only 66% and a 
moderately good specificity of only 82% of M30 plasma levels 
in diagnosing NASH.14
Regarding ALD, the diagnostic value of levels of M30 levels 
has been studied only in one very recent study. Mueller and 
co-workers measured serum concentrations of total K18 frag-
ments (M65) and caspase-cleaved M30 levels in actively drink-
ing alcoholic patients referred for alcohol detoxification who 
also underwent liver biopsy.15 Authors considered a panel of 
key laboratory and histological features of ALD and found sig-
nificant correlations between both, M65 and M30 levels, with 
histological apoptosis, ballooning, Mallory-Denk bodies, and 
steatosis, but interestingly, less so with fibrosis. However, the 
latter is crucial since fibrosis at any stage is considered the hall-
mark lesion in predicting progression to cirrhosis.16,17 To validate 
the diagnostic usefulness of plasma M30 levels to noninvasively 
assess alcoholic liver fibrosis, we assessed their correlation with 
fibrosis stages in a cohort of patients with ALD and available 
liver histology.
MATERIALS AND METHODS
1. Patients and samples
The study protocol was approved by the Cantonal Ethic Com-
mittee of Bern (No. KEK BE 062/11), Switzerland, and all pa-
tients gave written informed consent prior to inclusion for the 
present study. Alcoholic patients were included into the study 
(Inselspital, n=74; Clinic Beau-Site, n=38) once they became 
abstinent, and if they met the following criteria: (1) liver disease 
due to excessive alcohol consumption; (2) exclusion of other 
causes of liver disease; (3) available serum samples with match-
ing standard liver enzyme values; and (4) available liver biopsy. 
All subjects were assessed for their previous individual drink-
ing behavior. Liver damage was considered as alcohol-related 
in those with a reported alcohol history of >60 g/daily in males 
and >30 g/daily in females. Patients who were positive for 
hepatitis B surface antigen, anti-hepatitis C IgG, anti-nuclear 
antibodies above 1:80 and anti-mitochondrial antibodies above 
1:40, and reported regular (daily) cannabis consumption were 
excluded. All patients who presented with elevated serum fer-
ritin levels together with an increased transferrin saturation 
(>50%) were genotyped for hemochromatosis gene mutations, 
and excluded if found homozygous for the C282Y mutation. To 
exclude patients with any severe extrahepatic inflammatory or 
infectious condition, serum levels of C-reactive protein had to 
be below 20 mg/L at the time of inclusion into the study. All 
patients underwent a percutaneous liver biopsy, and histology 
was examined according to Kleiner et al.18 This score reflects 
the extent of histological damage of hepatocytes, combining 
the degree of fibrosis on a 5-point scale from 0 to 4, and the 
degree of inflammatory activity on a 4-point scale from A0 to 
A3. Patients were then divided into five subgroups according to 
their Kleiner-score according to the fibrotic stage (F0, F1, F2, F3, 
and F4). Fibrosis was visualized by Sirius Red staining applying 
standard protocols. Further, plasma M30 levels were measured 
in 29 healthy control subjects (75.9% male) with no evidence of 
liver injury and only occasional alcohol consumption.
Plasma samples were collected from a peripheral blood draw 
at the Department of Visceral Surgery and Medicine, Insel-
spital Bern and the Hepatology Unit, Klinik Hirslanden Beau-
Site, Bern, both in Switzerland, and stored at –80°C until being 
processed. Quantification of plasma M30 levels was performed 
using the M30-Apoptosense ELISA according to the manufac-
turer’s instructions (Catalog Prod No.10010; Peviva AB, Axxora 
GmbH, Germany). Results are provided in serum M30 levels as 
units per liter with an upper limit of normal (ULN) of 200 U/L.14 
All values were determined in duplicates.
All other laboratory variables were determined by means of 
routine diagnostic procedures established in the two hospitals. 
Reference ranges for routine laboratory values were identical in 
the two hospitals.
2. Statistics
Statistical analyses were performed using STATA 15.1. Data 
are expressed as means (±standard deviation [SD]) or count 
(%) as indicated. The statistical significance of differences was 
evaluated using chi-square test or the nonparametric analysis 
of variance Kruskal-Wallis test. To assess trends over fibrosis 
stage, logistic regression was performed using fibrosis stage as 
continuous variable as predictor. To assess correlations between 
variables, the Pearson’s correlation coefficient and the Spear-
man rho were calculated. Sensitivity, specificity, positive and 
negative predictive values were calculated for M30 levels and 
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liver cirrhosis (F4) and severe fibrosis (F2-4). A two-sided p-
value of <0.05 was considered statistically significant. 
RESULTS
In the present study, 139 consecutive patients with ALD re-
ferred to our liver clinic for diagnostic work-up were included 
(Inselspital, n=74; Clinic Beau-Site, n=38). Mean age of the 
patients was 57.6 years (SD, 10.1) while 110 patients were male 
(79.1%) (Table 1). Most patients had a fibrosis stage of F4 (51.7%) 
followed by F2 (25.2%). While the groups were relatively well-
matched for gender, age and body mass index, patients with 
fibrosis stage F2 and 3 had higher AST levels (mean, 101.2 U/L; 
SD, 82.1) than those with no or minimal fibrosis (mean, 60.1 U/L; 
SD, 49.6) (p=0.02). There was no difference for ALT levels (mean, 
112.5 U/L; SD, 23.5; mean, 62.0 U/L; SD, 70.9; respectively, 
p=0.13) between those two groups. Mean plasma M30 levels in 
healthy control subjects were 164 U/L (SD, 46.9). There was a 
trend towards higher plasma M30 levels with increasing fibro-
sis stages, but there was a large variation within groups (p for 
trend=0.14) (Table 1, Fig. 1). According to this variability, our 
data demonstrate only a small strength of correlation between 
M30 levels and fibrosis (Pearson’s correlation coefficient, 0.13; 
Spearman rho=0.20 [p=0.02]) (Fig. 1). Besides the large varia-
tion of M30 levels within individual fibrosis stage groups, there 
was also no significant difference between the fibrosis stages 
(p=0.44) (Fig. 1). There was a trend that mean M30 levels were 
higher among patients with significant fibrosis (≥F2) (mean, 674 
U/L; SD, 679) compared to patients without significant fibrosis 
(F0 and F1) (mean, 411 U/L; SD, 552), but this failed to reach 
significance (p=0.06).
However, we found a significant correlation of serum M30 
levels with AST (Spearman rho=0.653, p<0.001) and with ALT 
(Spearman rho=0.432, p<0.001) (Fig. 2). Considering an ULN for 
serum M30 levels of 200 U/L, the proportions of patients with 
normal M30 levels within the different fibrosis stage groups F0 
to 4 were 43%, 33%, 31%, 18%, and 16%, respectively (p for 
trend=0.01). The mean AST level among patients with normal 
M30 levels was 42.1 U/L (SD, 32.7) while it was 116.2 U/L (SD, 
220.8) among patients with elevated M30 levels (p=0.05). Mean 
ALT levels were higher among patients with elevated M30 levels 
(87.7 U/L; SD, 134.4) compared to those with normal M30 levels 
(37.1 U/L; SD, 37.6; p=0.03). 
There was no correlation between M30 levels and other key 
lesions of alcoholic liver injury including ballooning, steatosis, 
inflammatory activity or the presence of Mallory-Denk bodies 
(data not shown). 
Sensitivity of the cutoff value of 200 U/L to predict liver cir-
Table 1. Demographics and Plasma M30 Levels
Fibrosis stage
p-value*
F0 F1 F2 F3 F4
No. of patients 14 (10.1) 15 (10.8) 35 (25.2) 17 (12.2) 58 (51.7)
Age, yr 59.1±8.1 56.2±13.5 57.8±10.1 54.2±10.7 58.5±9.4  0.56*
Sex 0.94
Female 2 (14.3) 4 (26.7) 7 (20.0) 4 (23.5) 12 (20.7)
Male 12 (85.7) 11 (73.3) 28 (80.0) 13 (76.5) 46 (79.3)
BMI, m2/kg 26.3±2.6 26.4±3.2 24.8±4.7 24.6±1.9 27.4±5.8 0.12
ALT, U/L 47±34.7 76.1±92.2 111.6±166.5 114.4±181.0 48.7±68.1 0.07 (p-trend, 0.40)
AST, U/L 56.4±52.3 63.5±48.6 97.0±73.4 109.8±99.6 114.3±289.5 0.82 (p-trend, 0.23)
M30, U/L 409.9±567.9 413.0±556.5 669.0±659.2 727.3±792.8 661.8±666.3 0.44 (p-trend, 0.14)
M30 >200 U/L 8 (57.1) 10 (66.7) 24 (68.6) 14 (82.4) 49 (84.5) 0.13 (p-trend, 0.01)
Data are presented as number (%) or mean±SD.
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*Chi-square test.
Fibrosis stage as assessed by Kleiner et al.18
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Fig. 1. M30 serum levels in patients with alcoholic liver disease as 
assessed histologically for fibrosis by Kleiner et al.18 (no fibrosis=14; 
fibrosis stage I=15; stage II=35; stage III=17; and stage IV=58). 
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rhosis (F4) was 84.5% while its specificity was only 30.9%. The 
positive predictive value was 46.7% with a negative predictive 
value of 73.5%. To predict at least severe fibrosis (F2-4), the 
sensitivity of the cutoff value of 200 U/L was 79.1% with a 
specificity of 37.9%. The positive predictive value was 82.9% 
with a negative predictive value of 32.4%. 
DISCUSSION
The presented data clearly demonstrate that M30 levels >200 
U/L are often found among patients with ALD with increasing 
severity of chronic liver damage as reflected by histological 
fibrosis. M30 levels also correlate with serum AST levels and–
albeit to a lesser extent–with hepatocyte-specific ALT activities. 
However, in a relevant proportion of 15% to 31% of patients 
with ALD, serum M30 levels were low despite the presence of 
relevant fibrosis (F2-F4) and elevated serum liver enzymes. Our 
data comply with the data by Mueller et al.15 who demonstrated 
similar correlations of M30 levels with serum liver enzyme lev-
els. In as such, M30 levels can be considered relatively specific 
for alcohol-mediated liver injury in which AST elevations are 
often more profound than those of ALT, resulting in an eleva-
tion of the so-called De Ritis ratio above 1.19 Importantly, plas-
ma M30 levels represent circulating K18 fragments cleaved by 
caspases from the cell membranes of epithelial cells and appear 
in peripheral blood when these cells undergo apoptosis. For this 
reason, common cognition is that elevated M30 levels reflect 
ongoing apoptosis/cell death rather than inflammation and/or 
fibrosis.20 
Unlike in the study by Mueller et al,15 we found no significant 
correlation between M30 levels and the presence of ballooning, 
steatosis, inflammatory activity or Mallory-Denk bodies. This 
discrepancy may be due to the fact that patients in the Muel-
ler et al. study underwent a liver biopsy while still being ac-
tive drinkers or shortly thereafter, a time point when apoptosis 
might have been most pronounced or still ongoing. However, 
our patients were biopsied upon abstinence and much of the 
preexisting apoptosis may have disappeared by the time of the 
biopsy. Another reason for the lack of correlation with key fea-
tures of ALD in our study could be the usage of routine biopsies 
in which we performed no immunohistochemistry staining for 
apoptosis or K8/K18, the two single features, which showed the 
strongest correlation with M30 levels in the study performed by 
Mueller et al.15
So far, the present study is only the second clinical report 
investigating the diagnostic utility of circulating plasma levels 
of M30, for example, caspase-cleaved K18 fragments, in various 
fibrosis stages of ALD. Our essentially negative findings with 
regard to a possible association with fibrosis, however, provide 
interesting information in as such they show that plasma M30 
levels reflect hepatocellular damage mirrored by elevated serum 
transaminases. Here, M30 levels correlate slightly better with 
AST levels than with ALT, and therefore seem to reflect hepa-
tocyte damage just as serum transaminases do. The positive 
correlation between serum M30 levels and plasma liver enzyme 
activities has also been demonstrated by other researchers. For 
example, Sgier et al.21 showed the positive impact of a success-
ful antiviral therapy on circulating M30 levels in patients with 
chronic hepatitis C. Although correlations between M30 levels 
and serum transaminase levels were significant but weak, ther-
apy responders showed both decreasing liver enzyme and M30 
levels. 
More recent data from the CANONIC study show that plasma 
M30 and M65 levels are increased with increasing severity 
in cirrhotic patients with acute decompensation or acute on 
chronic liver failure.22 Interestingly and confirming our data, 
a background of alcohol abuse was associated with increased 
cell death markers whereas underlying infection was not. It has 
to be emphasized that infection as a potential confounder in 
our cohort was excluded prior to inclusion of patients into the 
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Fig. 2. (A) Correlation of K18 fragments with aspartate aminotransferase (AST). (B) Correlation of K18 fragments with alanine aminotransferase 
(ALT). Gray-shaded area refers to confidence interval.
Schlossberger V, et al: K18 Fragments in ALD  81
study. McDonald and coworkers demonstrated a close correla-
tion between the cell death markers M30 and M65 and markers 
of systemic inflammation, hepatic failure, ALT and bilirubin 
but not with markers of extrahepatic organ injury. The signifi-
cance of keratins as type II acute-phase responsive genes had 
been convincingly demonstrated in a clinical study using liver 
biopsies from patients with ALD, nonalcoholic steatohepatitis, 
chronic hepatitis B and C and from control subjects by measur-
ing hepatic mRNA expression of K7, K8, K18 and K19.23 All 
keratins were overexpressed 1.5- to 3-fold, particularly in sub-
jects with moderate versus minimal inflammation, and K8 and 
K18 were closely correlated with ALD. 
Interestingly, the same group of researchers also identified 
polymorphic variants in the genes coding for K18 and K8 as 
genetic susceptibility loci for acute liver failure24 and severely 
progressing primary biliary cholangitis,25 adding to the persua-
sion that the gene products, K8 and K18, play indeed a role in 
the progression of chronic fibrosing liver disease, and possibly, 
associated complications. Regarding the latter, Mueller et al.15 
have suggested that both elevated M30 and M65 levels are pre-
dictors of increased non-HCC liver-related mortality with cutoff 
values of M65 levels >650 U/L and M30 >255 U/L, respectively. 
This assumption is supported by another recent study which 
determined whether M65 or M30 plasma levels were different 
between patients with alcoholic cirrhosis and alcoholic hepati-
tis.26 Compared to alcoholic cirrhotics, patients with alcoholic 
hepatitis revealed significantly higher M30 and up to 5-fold 
higher M65 levels, and the M30/M65 ratio outscored the Model 
for End-stage Liver Disease and age, serum bilirubin, INR, and 
serum creatinine (ABIC) prognostic scores to predict survival.
In a similar but larger recent clinical study, Bissonnette et al.27 
tested the diagnostic utility of M30 and M65 plasma levels to 
identify patients with severe alcoholic hepatitis. Both M30 and 
M65 levels were elevated in alcoholic hepatitis patients, and 
both markers had an area under the receiver operating char-
acteristics curve of 0.84 to estimate the presence of AH. Par-
ticularly good was the performance of M65 with positive and 
negative predictive values of 91% and 88%, respectively, for the 
presence of histological alcoholic hepatitis.
The bottom line of these and our data is that M30 levels are 
often elevated in ALD, and likely in other chronic liver diseases. 
It shows a significant correlation with serum transaminase 
levels and thus reflects acute hepatocyte damage, but a close 
correlation to the fibrotic stage could not be shown so far. 
However, as an additional application, M30 levels may be used 
as a prognostic marker to predict mortality, although it remains 
open how an elevated marker of acute liver injury translates 
into a prediction of long-term prognosis in ALD. Clearly, more 
research on the causes of death in those with elevated M65/M30 
levels is required to dissect liver-related from non-liver related 
causes of increased mortality.
It has to be conceded that our study has several weaknesses 
and limitations. First, we have no data on M65 plasma or serum 
levels, since this was not considered relevant at the time the 
study was conceived. Retrospective re-analysis of stored plasma 
samples is not an option since these samples are no longer 
available. Second, we have no long-term prospective data on 
the course of the disease of the included patients which prevents 
any conclusions on the value of M30 as a predictor of mortality 
or survival, respectively. Also, liver lesions other than fibrosis 
were not further explored by additional investigational steps 
such as specific immunohistology stainings. At the time the 
study was initiated, expectations towards M30 as a marker of 
fibrosis prevailed all other possible applications. 
However, strengths of our data are that all patients had 
available liver histology with scored fibrosis stages in all, and 
matched M30 measurements. Our study cohort has a consider-
able size in a chronic liver entity that is less frequently studied. 
We attest that the M30 level at the present time has no role as 
a fibrosis marker, but rather serves as a marker of acute liver 
damage similar to serum liver transaminases. Further studies 
should elucidate the potential role of M30 and M65 as a predic-
tor of mortality in alcoholic cirrhosis and alcoholic hepatitis in 
prospective studies to establish its usefulness as a prognostic 
marker, possibly also to improve organ allocation in liver trans-
plantation programs.
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